VKH
GALT icon

Virtu KCG Holdings’s Galectin Therapeutics GALT Stock Holding History

Virtu KCG Holdings’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$264K Buy
107,203
+21,008
+24% +$56K 0.01% 1828
2017
Q1 		$198K Buy
86,195
+1,592
+2% +$2.4K 0.01% 2434
2016
Q4 		$83K Sell
84,603
-16,355
-16% -$14.5K ﹤0.01% 2970
2016
Q3 		$114K Buy
+100,958
New +$179K ﹤0.01% 2598
2016
Q2 		– Sell
-10,437
Closed -$15K – 3073
2016
Q1 		$15K Sell
10,437
-26,927
-72% -$36.2K ﹤0.01% 2623
2015
Q4 		$61K Buy
37,364
+22,614
+153% +$51.8K ﹤0.01% 3120
2015
Q3 		$35K Sell
14,750
-52,383
-78% -$124K ﹤0.01% 3070
2015
Q2 		$183K Buy
+67,133
New +$202K ﹤0.01% 2649
2015
Q1 		– Sell
-39,823
Closed -$138K – 3396
2014
Q4 		$138K Buy
+39,823
New +$176K ﹤0.01% 3080

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu KCG Holdings's GALT Position: Q2 2017 in Review

Virtu KCG Holdings increased its Galectin Therapeutics (GALT) stake by 24% in Q2 2017, buying an estimated $56K and bringing the position to 107,203 shares worth $264K. The position accounts for 0.01% of the portfolio, ranked #1828.

Virtu KCG Holdings first reported a position in GALT in Q4 2014 and has held it in 9 quarters since. 52 funds tracked by Wall St. Rank hold GALT as of Q2 2017.

  • Virtu KCG Holdings held 107,203 shares of Galectin Therapeutics worth $264K as of Q2 2017.
  • Virtu KCG Holdings bought 21,008 Galectin Therapeutics shares in Q2 2017, an estimated $56K.
  • Galectin Therapeutics made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #1828 holding.
  • Virtu KCG Holdings first reported a position in Galectin Therapeutics in Q4 2014 and has held it in 9 quarters since.
  • 52 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.